Ben Auspitz is listed as a director on 5 SEC Form D filings by 3 issuers between Jul 2014 and Apr 2025: Symbiomix Therapeutics, LLC (Newark, NJ — pharmaceuticals — 2014–2016; $19.5M reported sold to 5 investors), Meves Pharmaceuticals, Inc. (New York, NY — pharmaceuticals — 2018; $10.9M reported sold to 4 investors) and Zero Point Five Therapeutics, Inc. (Baltimore, MD — biotechnology — 2023–2025; $7.22M reported sold to 15 investors).
What this means A repeat sponsor — 3 separate companies raised money with this person listed as director, over about 11 years. Across those companies the filings report $37.7M sold in total.
Listed alongside Joseph Amprey III (4 shared filings), Rishi Gupta (3 shared filings), Jodi Jahic (2 shared filings), Klaus Veitinger (2 shared filings), Robert Jacks (2 shared filings) and 4 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Ben. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 5 public filings for Ben Auspitz and found 7 differences: Ben Auspitz appears on 1 deal that stopped filing before reaching its target; 4 offerings have no amendment in the last 12 months and may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.